Healthcare provider profile · identity verified

Angela M Cooper, PAC

Physician Assistant · LANSING, IA · NPI 1033193404

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Furosemide	Furosemide	317	37
Warfarin Sodium	Warfarin Sodium	258	14
Eliquis	Apixaban	222	20
Potassium Chloride	Potassium Chloride	220	26
Gabapentin	Gabapentin	207	27
Levothyroxine Sodium	Levothyroxine Sodium	202	24
Amlodipine Besylate	Amlodipine Besylate	191	25
Lisinopril	Lisinopril	187	22
Metoprolol Succinate	Metoprolol Succinate	170	25
Atorvastatin Calcium	Atorvastatin Calcium	150	23
Losartan Potassium	Losartan Potassium	116	17
Sertraline Hcl	Sertraline Hcl	114	16
Quetiapine Fumarate	Quetiapine Fumarate	111	suppressed
Tramadol Hcl	Tramadol Hcl	107	35
Mirtazapine	Mirtazapine	104	20
Famotidine	Famotidine	98	12
Metoprolol Tartrate	Metoprolol Tartrate	96	16
Bumetanide	Bumetanide	90	13
Tamsulosin Hcl	Tamsulosin Hcl	88	12
Fentanyl	Fentanyl	87	suppressed
Omeprazole	Omeprazole	86	20
Lorazepam	Lorazepam	84	21
Duloxetine Hcl	Duloxetine Hcl	82	16
Allopurinol	Allopurinol	81	11
Pantoprazole Sodium	Pantoprazole Sodium	64	suppressed
Donepezil Hcl	Donepezil Hcl	63	11
Spironolactone	Spironolactone	63	13
Hydroxyzine Hcl	Hydroxyzine Hcl	60	11
Albuterol Sulfate	Albuterol Sulfate	56	36
Trazodone Hcl	Trazodone Hcl	53	13
Simvastatin	Simvastatin	52	suppressed
Xarelto	Rivaroxaban	51	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	46	suppressed
Ondansetron Hcl	Ondansetron Hcl	45	suppressed
Loperamide	Loperamide Hcl	44	14
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	42	suppressed
Clopidogrel	Clopidogrel Bisulfate	42	suppressed
Carvedilol	Carvedilol	41	suppressed
Pregabalin	Pregabalin	40	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	40	suppressed
Memantine Hcl	Memantine Hcl	39	suppressed
Fluticasone Propionate	Fluticasone Propionate	37	11
Torsemide	Torsemide	37	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	36	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	36	suppressed
Finasteride	Finasteride	35	suppressed
Citalopram Hbr	Citalopram Hydrobromide	34	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	34	suppressed
Jardiance	Empagliflozin	34	suppressed
Nystatin	Nystatin	33	20
Rosuvastatin Calcium	Rosuvastatin Calcium	33	suppressed
Buspirone Hcl	Buspirone Hcl	32	suppressed
Hydrocortisone	Hydrocortisone	31	15
Escitalopram Oxalate	Escitalopram Oxalate	30	suppressed
Metformin Hcl	Metformin Hcl	28	suppressed
Nyamyc	Nystatin	28	13
Propranolol Hcl	Propranolol Hcl	28	suppressed
Levetiracetam	Levetiracetam	27	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	26	suppressed
Farxiga	Dapagliflozin Propanediol	25	suppressed
Ropinirole Hcl	Ropinirole Hcl	25	suppressed
Cholestyramine	Cholestyramine (With Sugar)	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Novofine Autocover	Pen Needle, Diabetic, Safety	24	suppressed
Prednisone	Prednisone	23	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	22	18
Oxycodone Hcl	Oxycodone Hcl	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Clonazepam	Clonazepam	20	suppressed
Lansoprazole	Lansoprazole	20	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Risperidone	Risperidone	20	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	20	14
Glipizide	Glipizide	19	suppressed
Methocarbamol	Methocarbamol	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Cefadroxil	Cefadroxil	18	14
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	18	suppressed
Baclofen	Baclofen	17	suppressed
Carbamazepine Er	Carbamazepine	17	suppressed
Novolog Flexpen	Insulin Aspart	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Aripiprazole	Aripiprazole	15	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Ondansetron Odt	Ondansetron	15	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	15	suppressed
Sucralfate	Sucralfate	15	suppressed
Atenolol	Atenolol	14	suppressed
Divalproex Sodium	Divalproex Sodium	14	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Diltiazem Hcl	Diltiazem Hcl	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Galantamine Hbr	Galantamine Hbr	12	suppressed
Haloperidol	Haloperidol	12	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Zonisamide	Zonisamide	12	suppressed
Alprazolam	Alprazolam	11	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Dropsafe Pen Needle	Pen Needle, Diabetic, Safety	11	suppressed
Naproxen	Naproxen	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error